GlassScriptPhysician profile
Christopher J Salmon
NPI 1164884177
$54,059.19
in general payments reported to CMS, 2019-2025
18 companies · $2,489 in 2025
The $2,489 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $83.31 · 2021: $356 · 2022: $468 · 2023: $50K · 2024: $192 · 2025: $2,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $50K · Food and Beverage: $1,616 · Travel and Lodging: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $50,000.00 |
| Food and Beverage | $1,616.26 |
| Travel and Lodging | $1,221.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $50,000.00 | 2023 | Corevalve Evolut R |
| Siemens Medical Solutions USA, INC. | $1,070.85 | 2025 | Somatom Pro.Pulse, Naeotom Alpha, Magnetom Sola |
| Heartflow, INC. | $928.51 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $428.57 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $377.54 | 2019-2025 | Watchman Flx, Farapulse, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $283.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.75 | 2021-2025 | Farxiga |
| Philips North America LLC | $172.29 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Amgen INC. | $153.48 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $149.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.24 | 2022-2023 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $31.57 | 2022 | |
| Alliance Medical | $15.11 | 2025 | |
| Terumo Medical Corporation | $14.75 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.40 | 2019 | |
| Lantheus Medical Imaging, INC. | $13.35 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Salmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.